SAN DIEGO, Sept. 28 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals, Inc. will be presenting at the Sachs Associates 6th Annual Biotech in Europe Investor Forum on Wednesday, October 4, 2006 at 11:35 AM Central European Summer Time. Todd Myers, chief financial officer of SGX Pharmaceuticals, will provide a corporate overview on the Company’s oncology pipeline. The conference is being held October 4-5 at the Swissotel in Zurich, Switzerland.
A live webcast of the presentation will be available under the investor relations section of the Company’s website at www.sgxpharma.com. Replays of the presentation will be available for 90 days following the event. Please connect to the Company’s website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About SGX Pharmaceuticals
SGX Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics. SGX’s oncology pipeline includes Troxatyl as well as drug candidates from its enabling, proprietary FAST(TM) drug discovery platform, including next generation BCR-ABL inhibitors currently being developed in partnership with Novartis. More information on the pipeline and drug discovery platform can be found at www.sgxpharma.com and in the Company’s various filings with the Securities and Exchange Commission.
SGX Pharmaceuticals, Inc.
CONTACT: Todd Myers, Chief Financial Officer of SGX Pharmaceuticals,+1-858-558-4850; or Jason Spark, Media & Investor Relations of PorterNovelli Life Sciences, +1-619-849-6005, for SGX Pharmaceuticals, Inc.
Web site: http://www.sgxpharma.com/
